Web Research

Web Research — Lee & Man Chemical (0746)

The web adds three things the filings cannot: a real-time read on caustic soda and thermal coal pricing, independent commentary on the Lee family's control structure and its paper-making affiliate, and the industry backdrop that explains why the shares rallied from HK$3.41 in May 2025 to HK$6.42 in February 2026 before pulling back to HK$4.85. What the web research does not find is equally informative — no analyst coverage from global brokers, no SEC or SFC enforcement action, and no controversy around the announced chairperson succession.

The Bottom Line from the Web

Lee & Man Chemical is a pure proxy for the Chinese chlor-alkali cycle, a small family-controlled issuer with extraordinary insider ownership and no visible sell-side coverage. The single most important thing the web reveals that the filings do not is the cyclical context: China caustic soda prices have compressed to roughly 800–900 RMB/tonne through most of 2025 after ranging 2,400–3,200 RMB/tonne in 2024, while thermal coal — the dominant variable cost for captive chlor-alkali power — is forecast to average only 660 yuan/t at Qinhuangdao in 2026 versus the approximately 830 yuan/t spike of late 2024. Lee & Man is therefore entering 2026 with ECU margins squeezed on the revenue side but relieved on the cost side, which is the structural story behind the dividend yield of 6.9–7.1% and the 0.65x price-to-book that Morningstar's quantitative model flags.

What Matters Most

**1. Caustic soda pricing has collapsed into the cost curve — but so has coal.** SunSirs' 2025 review shows Chinese caustic soda averaging 887 RMB/t in early April 2025 and falling to 835 RMB/t by end-June, with Q3 prints around 833 RMB/t. Independent pricing services put China FOB caustic soda at roughly US$100–120/MT for most of late 2025 (versus US$415/MT FOB USA in February 2026), confirming China is the low-cost global source. Simultaneously, Bloomberg Intelligence expects Qinhuangdao Q5500 thermal coal to average 660 yuan/t in 2026, and the National Development and Reform Commission fixed the 2026 power-coal benchmark at 675 yuan/t (unchanged from 2025). Lee & Man's unit economics are therefore being rebuilt from the cost side even as the revenue side remains weak.

**2. China's chemical industry is still in "involution" — capacity cuts are slow.** Chemical & Engineering News (published January 2026) states outright that "overcapacity will continue to plague China's chemical industry in 2026" and that Beijing's anti-involution policy "is likely to have little impact." A separate industry analysis notes the MIIT published a mandatory national standard on 29 April 2024 setting energy consumption limits for caustic soda, PVC and chloromethanes effective 1 May 2025 — this is the most concrete supply-side discipline mechanism visible in the data, but results still lag. ResourceWise's 2025/2026 chlor-alkali review concludes "expectations for 2026 remain muted" with no significant caustic soda demand growth.

**3. A tightly held float with 75% insider ownership — institutional presence is negligible.** Market screener data shows Mr. Man Yan Lee (CEO) holds 65% (536.25 million shares) and Ms. Siu Kee Wai (executive chairman) holds 10% (82.5 million shares), with the "free float" at roughly 25%. StockDetect confirms "institutional shareholders 3.23%, insiders 75.00%." SLGI Asset Management is the only named institutional holder and owns 18,000 shares (0.002%). This confirms filings-side evidence of concentrated family control and explains why 13F-style fund flow is not a relevant variable for this stock.

**4. The 52-week range tells the swing story.** Lee & Man traded between HK$3.41 (13 May 2025) and HK$6.42 (9 February 2026) — an 88% trough-to-peak rally that compressed back to HK$4.85 by 17 April 2026. The same period saw FY2024 revenue (HK$3.76B TTM) and 14.9% net margin prints; the rally tracks the industry narrative around MIIT energy-consumption limits taking effect May 2025 and the subsequent partial roll-back of that optimism as caustic prices weakened through Q3–Q4 2025.

**5. Zero global sell-side coverage, unusually reliant on quantitative fair-value marks.** No research reports from HSBC, CICC, Macquarie, UBS, Goldman, Morgan Stanley or JP Morgan surface in the data — only quantitative fair-value calibrations (Morningstar: HK$4.41 with "Medium" uncertainty, implying the current HK$4.85 is at a slight premium; Simply Wall St: fair value materially above spot, implying a 51.6% discount; no consensus target price). An investor owns this name without the safety net of broker-research refresh cycles; pricing is driven by retail flows, passive Hong Kong index inclusion, and the controlling-family narrative.

6. The fluoropolymer and lithium-additive expansion remains thinly disclosed on the public web. The 2017 Gaolan Port announcement still anchors public understanding of the new-materials build-out: 800 million yuan (approximately US$121M) expected revenue eventually, US$54M total cost with US$35M fixed assets, phased commissioning with a "first phase by end of December 2018" and a "second phase operations by end of November 2021." The company's corporate site confirms that three bases — Changshu, Ruichang and Gaolan — are operating and that "the Group is actively planning to develop a high-end fluoropolymer production line at the new site in Jiangxi." No 2025/2026 capex guidance, commissioning schedule, or ramp-rate specifics for PTFE/FEP/HFP are visible in the public data — this is a gap the filings and transcripts must fill.

7. Family affiliate Lee & Man Paper (2314.HK) is a captive demand signal. The Lee family controls both issuers: Raymond Lee Man-chun (chairman of 2314) and Lee Man-bun (CEO of 2314) sit on top of a 51%-minimum lock-in covenant in 2314's 2017 facility agreement — the family must retain at least 51% of 2314 for the loan to remain outstanding. Lee & Man Paper is a large pulp producer (approximately US$3B revenue, around 10,000 employees, plants in Guangdong/Jiangsu/Jiangxi/Chongqing/Vietnam) that consumes caustic soda for pulp processing. This is a material related-party demand pipeline worth monitoring, though the web data does not disclose transfer-pricing terms or captive volumes.

8. No environmental or regulatory controversies surface. The targeted search for "Lee & Man Chemical Jiangsu Jiangxi environmental violation EPA fine chlor-alkali pollution 2022–2025" returned only generic US EPA enforcement pages — no Chinese MEE, provincial EPA, or HK listings-rule sanction against 0746 appears in the public web. Similarly the "scandal / controversy / SEC investigation" searches returned no hits. This is a clean record on publicly discoverable enforcement actions over the window examined.

9. The succession question is unanswered by the web. A direct search for "Ms. Wai Siu Kee succession plan Lee & Man retirement 2025 2026" returned unrelated Singapore politics content — the web has no signal that the executive chairman is stepping down or that a named successor has been identified beyond Man Yan Lee, who has served as CEO since 1 August 2014. Governance-advisory coverage (ISS / Glass Lewis) is also absent.

10. Employee footprint is tiny versus revenue scale. LinkedIn company pages list 145–169 employees visible; CNBC's company profile reports 1,900 total staff. For a business generating HK$3.75B TTM revenue with 34.5% gross margin, this implies a highly capital-intensive, low-headcount chlor-alkali process operation — consistent with the industry pattern but a long way from the labour intensity of the affiliated paper business (2314's approximately 10,000 staff).

Headline Valuation Snapshot

Share Price (HK$)

4.85

Market Cap (HK$B)

4.00

P/E (TTM)

7.2

Dividend Yield (%)

6.9

Price / Book

0.65

Net Margin TTM (%)

14.9

ROE TTM (%)

9.1

Beta (5Y)

0.49

Web-sourced reference points as of 17 April 2026: 52-week range HK$3.41–6.42; TTM revenue HK$3.76B; TTM EBITDA HK$821M; gross margin 34.48%; debt-to-equity 12.4%. Two independent quantitative fair-value estimates diverge widely — Morningstar's quantitative model marks fair value at HK$4.41 (slight overvaluation at spot), while an alternative narrative-based model flags roughly 51.6% undervaluation. No broker consensus target price is published.

Caustic Soda Price Arc — The Macro Variable

Two distinct reference series run through the web data. The first is the 2024 domestic-spot range of RMB 2,400–3,200 per tonne documented by CAMAL Group. The second is the sharply lower 2025 level (roughly RMB 830–900 per tonne) documented by SunSirs' 2025 market review and early-2026 commentary. Independent FOB quotes (ProcurementResource, IMARC) cluster China export prices at US$90–120 per tonne across late 2025 and early 2026 — a fraction of US$415 per tonne FOB USA and US$400 per tonne FOB Germany. The message: Chinese domestic producers are already clearing at international cost-curve prices. The variable that matters most for Lee & Man's 2026 margin is not whether caustic soda prices rise, but whether Chinese thermal coal — and hence captive power cost — stays at the 660 yuan per tonne level that Bloomberg Intelligence forecasts.

Recent News Timeline

No Results

The two regulatory dates anchor the entire 2025 price-action narrative: the 29 April 2024 publication of MIIT's mandatory national standard and its 1 May 2025 effective date. The market bottomed the same month the rule took effect (HK$3.41 on 13 May 2025), rallied 88% into the February 2026 peak on the expectation of supply discipline, and then gave back roughly a third of those gains when caustic soda prices continued to drift through Q3–Q4 2025. No direct material news on Lee & Man — no M&A, no capital raise, no board change, no enforcement action — surfaces in the web record for this window.

What the Specialists Asked

Insider Spotlight

No Results

The control structure is as binary as it gets. Two individuals own three-quarters of the company. The 2314-style 51% family lock-in covenant used by Lee & Man Paper with its lenders is a pattern that signals how the family views control — as a contractual precondition for debt capacity, not merely a voting convenience. For Lee & Man Chemical itself, no insider-selling or Form-4-equivalent transactions surface in the web data; the absence is expected given Hong Kong's disclosure threshold and the fact that a 65% holder is unlikely to trim in small increments without triggering market and SFC attention.

Industry Context

Three structural forces dominate the industry outlook. First, overcapacity is not being solved by administrative fiat — the 29 April 2024 MIIT energy-consumption standard has created compliance pressure (effective 1 May 2025) but the independent trade press is uniformly cautious that this will translate into actual shutdowns. Second, the Carbon Border Adjustment Mechanism (CBAM) entered its reporting phase in 2026 and creates compliance overhead for EU-bound chlor-alkali derivatives, marginally favouring larger, more integrated producers like Lee & Man over small captive shops. Third, downstream demand is bifurcating — EV and solar-related materials (electrolyte additives, fluoropolymers for wire insulation) grow rapidly, while legacy end-uses (alumina, construction) remain soft. Lee & Man's fluoropolymer and lithium-additive expansion is directly aligned with the growth half of that bifurcation, which is the strongest strategic signal in the public data even though specific capacity numbers and commissioning dates remain undisclosed on the open web.

What the Web Does Not Reveal

A short list of material questions that the web research could not answer, and which the filings and transcripts layer must address: specific PTFE / FEP / HFP commissioning dates and Jiangxi capex envelope; captive caustic soda volumes and transfer-pricing terms with Lee & Man Paper (2314); any succession or retirement framework for the executive chairman; quarter-by-quarter ECU spread and cash cost per tonne; exposure to the EU via CBAM-relevant downstream shipments; and any environmental compliance costs associated with the May 2025 MIIT rule. These are the handoffs from web research into the internal specialist analyses.